Research and Markets (http://www.researchandmarkets.com/research/f32c55/lung_cancer_drug_p)
has announced the addition of the "Lung
Cancer Drug Pipeline Update 2010" report to their offering.
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
comprises over 95% of all lung cancers. High unmet needs still persist
for this tumor type and despite two decades of extensive R&D and
chemotherapy use, the median overall survival of NSCLC patients remains
below 12 months. Mesothelioma is rarer, although incidence is expected
to increase in the coming years in Europe and Japan given the heavy use
of asbestos in the 1970s and long latency period of the disease.
There are today 298 (265) companies plus partners developing 399 (352)
lung cancer drugs in 455 developmental projects in cancer. In addition,
the accumulated number of ceased drugs over the last years amount to
another 166 (117) drugs. Lung Cancer Drug Pipeline Update lists all
drugs and gives you a progress analysis on each one of them. Identified
drugs are linked to 221 (181) different targets. These targets are
further categorized on the CD-ROM by 59 (55) classifications of
molecular function and with pathway referrals to BioCarta, KEGG and
NetPath. Figures in brackets are comparative data from last year.
Find and sort drugs by twelve different parameters plus free text search
field. Our dynamic report generator lets you with ease and speed
generate html reports directly in your web browser, whether it is a
single drug profile or an entire search you want have a report of.
How May Drug Pipeline Update Be of Use?